Monopar Therapeutics shares baseline disease burden data and long‑term safety results for ALXN1840 at AASLD meeting

Monopar Therapeutics presented baseline findings from its Phase 3 FoCus trial in Wilson disease at the AASLD conference in Denver. The data showed that among patients who had previously received therapy, roughly four in ten had cirrhosis, eight in ten exhibited neurologic signs and three‑quarters displayed psychiatric symptoms. A poster also reported that subjects on ALXN1840 maintained neutral molybdenum balance and normal uric‑acid levels over six years of treatment.

The company’s disclosure highlights the substantial unmet need in Wilson disease, suggesting a large market for an effective therapy. Investors should note that the long‑term safety profile of ALXN1840 may support future regulatory approval and commercial rollout.

  • 1The Phase 3 FoCus trial is the largest randomized controlled study ever conducted in Wilson disease.
  • 2Among treatment‑experienced participants, cirrhosis was present in 39% of patients.
  • 3Neurologic manifestations were observed in 79% of treatment‑experienced participants.
  • 4Psychiatric symptoms were reported in 75% of treatment‑experienced participants.
  • 5Seventy‑three percent of evaluable patients had at least two of cirrhosis, neurologic or psychiatric signs at baseline.
  • 6Neutral molybdenum balance and normal serum uric‑acid levels were maintained over six years of ALXN1840 treatment.

Sources